title: ADAPTIVE MECHANISMS OF THE IMMUNE SYSTEM IN CHILDREN IN FAR NORTH.
abstract: This article is devoted to the probleme of modern Pediatrics pathology of the immune system in children with complicated viral infections. The aim of this study was to investigate the immune and cytokine status in children with complicated acute respiratory viral infections. The study included 100 children are often ill respiratory virus infections (more than 8 times per year) from age 0 to 7 years, and 30 children with upper respiratory tract infection; no more than 1 time per year-the control group. The standards of indicators developed by the staff of Immunological laboratory Diagnostic center of the Ministry of health of Republic Sakha (Yakutia ) together with the Institute of health of the Republic Sakha (Yakutia). Statistical calculations made on the basis of applied programs "SAS"and "SPSS"In the analysis of contingency tables (estimates of the correlation of the characteristic and evaluation of significance of differences between groups) used the criterion of 2 (Pearson and likelihood ratio and Fisher's exact test. Comparison of mean values was performed univariate analysis of variance using T-student criterion for assessing the equality of mean F-Fisher test to assess equality of variance. Extreme climatic conditions ofthe far North have an impact on immunological mechanisms. In the analysis of changes ofthe immune status revealed the greatest decline in T-cell level and components of complement in children with complications of viral respiratory infections. In children with complicated respiratory viral infections reduced cellular immunity (CD3+, CD41, CD81, CD+, CD 22+). In children with complicated respiratory viral infections decrease levels ofcytokines (IFN-y FN0-d), indicating about the risk of the formation of complications of respiratory viral infections. As a result of drug therapy of broncho-vaxom marked improvement in immune status and the absence of recurrence of respiratory viral infections within the next 3 months after therapy.
authors.forename: O N
authors.initials: ON
authors.lastname: Ivanova
authors.forename: E F
authors.initials: EF
authors.lastname: Argunova
authors.forename: S N
authors.initials: SN
authors.lastname: Alekseev
authors.forename: T V
authors.initials: TV
authors.lastname: Ystugina
authors.forename: A R
authors.initials: AR
authors.lastname: Varfolomeev
authors.forename: I P
authors.initials: IP
authors.lastname: Troev
authors.forename: I V
authors.initials: IV
authors.lastname: Kononova
authors.forename: V E
authors.initials: VE
authors.lastname: Egorova
mesh_terms: D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D001110:Arctic Regions; D002457:Cell Extracts / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D003080:Cold Temperature; D016207:Cytokines / Q000276:immunology*; D005260:Female; D006801:Humans; D007107:Immune System; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D044382:Population Groups; D012141:Respiratory Tract Infections / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology*; D012426:Russia; D013601:T-Lymphocytes / Q000276:immunology*; D014777:Virus Diseases / Q000276:immunology*; D000095983:Bacterial Lysates
chemical_list: D000276:Adjuvants, Immunologic; D002457:Cell Extracts; D016207:Cytokines; C030259:Broncho-Vaxom; D000095983:Bacterial Lysates